Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Documented EGFR mutation~* Documented c-MET dysregulation~* Prior clinical benefit on EGFR inhibitors and then subsequent progression~  -≥ 18 year old~* Life expectancy of ≥ 3 months~* ECOG performance status ≤ 2~Exclusion Criteria:~* Unable to swallow tables once or twice daily~* Previous treatment with c-MET inhibitor~* Any unresolved toxicity from previous anticancer therapy greater than grade 1~* History of cystic fibrosis~* History of acute or chronic pancreatitis~* Unable to undergo MRI or CT scans~* Known history of HIV~* Undergone a bone marrow or solid organ transplant~* Clinically significant wound or lung tumor lesions with increased likelihood of bleeding~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INC280 100 mg Cap QD Phase Ib (Type: EXPERIMENTAL): cap=capsule; QD=once daily
- INC280 200 mg Cap QD Phase Ib (Type: EXPERIMENTAL): cap=capsule; QD=once daily
- INC280 400 mg Cap QD Phase Ib (Type: EXPERIMENTAL): cap=capsule; QD=once daily
- INC280 800 mg Cap QD Phase Ib (Type: EXPERIMENTAL): cap=capsule; QD=once daily
- INC280 200 mg Cap BID Phase Ib (Type: EXPERIMENTAL): cap=capsule; BID=twice daily
- INC280 400 mg Cap BID Phase Ib (Type: EXPERIMENTAL): cap=capsule; BID=twice daily
- INC280 600 mg Cap BID Phase Ib (Type: EXPERIMENTAL): cap=capsule; BID=twice daily
- INC280 200 mg Tab BID Phase Ib (Type: EXPERIMENTAL): tab=tablet; BID=twice daily
- INC280 400 mg Tab BID Phase Ib (Type: EXPERIMENTAL): tab=tablet; BID=twice daily
- INC280 400 mg Cap BID Phase II (Type: EXPERIMENTAL): cap=capsule; BID=twice daily
- INC280 400 mg Tab BID Phase II (Type: EXPERIMENTAL): tab=tablet; BID=twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).